Akari Therapeutics, Plc
AKTX
$3.06
-$2.09-40.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.34% | -0.53% | -12.61% | -20.43% | -5.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.63% | -28.79% | -33.17% | -16.34% | 5.27% |
| Operating Income | 31.63% | 28.79% | 33.17% | 16.34% | -5.27% |
| Income Before Tax | 7.53% | 16.36% | 39.07% | -8.17% | -97.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 12.60% | 21.75% | 39.07% | -8.17% | -97.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.60% | 21.75% | 39.07% | -8.17% | -97.75% |
| EBIT | 31.63% | 28.79% | 33.17% | 16.34% | -5.27% |
| EBITDA | 31.66% | 28.80% | 33.16% | 16.29% | -5.21% |
| EPS Basic | 75.04% | 79.12% | 80.00% | 56.18% | -1.50% |
| Normalized Basic EPS | 79.87% | 83.31% | 82.00% | 66.99% | 15.24% |
| EPS Diluted | 75.04% | 79.12% | 80.00% | 56.18% | -1.32% |
| Normalized Diluted EPS | 79.87% | 83.31% | 82.00% | 66.99% | 15.38% |
| Average Basic Shares Outstanding | 181.97% | 238.55% | 252.89% | 221.58% | 161.60% |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |